Co-Inhibitory Molecules – Their Role in Health and Autoimmunity; Highlighted by Immune Related Adverse Events
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Co-Inhibitory Molecules – Their Role in Health and Autoimmunity; Highlighted by Immune Related Adverse Events
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 13, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-06-16
DOI
10.3389/fimmu.2022.883733
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- T peripheral helper cells in autoimmune diseases
- (2022) Kathryne E Marks et al. IMMUNOLOGICAL REVIEWS
- Immune-checkpoint inhibitors: long-term implications of toxicity
- (2022) Douglas B. Johnson et al. Nature Reviews Clinical Oncology
- Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
- (2022) Hussein A. Tawbi et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Programmed Death-1 Pathway Counter-Regulates Inflammation-Induced Osteoclast Activity in Clinical and Experimental Settings
- (2022) Stinne R. Greisen et al. Frontiers in Immunology
- Immune Checkpoint Inhibitor-Induced Hypophysitis and Patterns of Loss of Pituitary Function
- (2022) Shlomit Jessel et al. Frontiers in Oncology
- Every two‐month belatacept maintenance therapy in kidney transplant recipients greater than one‐year post‐transplant: a randomized, non‐inferiority trial
- (2021) I. Raul Badell et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Outcomes of Patients With Interstitial Lung Disease Receiving Programmed Cell Death 1 Inhibitors: A Retrospective Case Series
- (2021) Ioana A. Dobre et al. Clinical Lung Cancer
- PD-L1 as a biomarker of response to immune-checkpoint inhibitors
- (2021) Deborah Blythe Doroshow et al. Nature Reviews Clinical Oncology
- TNF in the era of immune checkpoint inhibitors: friend or foe?
- (2021) Allen Y. Chen et al. Nature Reviews Rheumatology
- Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy
- (2021) E. Ghisoni et al. EUROPEAN JOURNAL OF CANCER
- Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-risk Resected Melanoma
- (2021) J. Randall Patrinely et al. JAMA Oncology
- CD4 T-Cell Exhaustion: Does It Exist and What Are Its Roles in Cancer?
- (2021) Alexandra M. Miggelbrink et al. CLINICAL CANCER RESEARCH
- Autoantibodies in Patients With Immune-Related Adverse Events From Checkpoint Inhibitors
- (2021) Nilasha Ghosh et al. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY
- Hypophysitis, the Growing Spectrum of a Rare Pituitary Disease
- (2021) Fabienne Langlois et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- IL-6 blockade for prophylaxis and management of immune-related adverse events (irAEs) with anti-PD-1 based immunotherapy.
- (2021) Florentia Dimitriou et al. JOURNAL OF CLINICAL ONCOLOGY
- Juvenile idiopathic arthritis: lymphocyte activation gene-3 is a central immune receptor in children with oligoarticular subtypes
- (2021) Erdal Sag et al. PEDIATRIC RESEARCH
- A LAG-3–Specific Agonist Antibody for the Treatment of T Cell–Induced Autoimmune Diseases
- (2020) Mathieu Angin et al. JOURNAL OF IMMUNOLOGY
- Molecular mechanism of SHP2 activation by PD-1 stimulation
- (2020) M. Marasco et al. Science Advances
- Association of Steroids use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
- (2020) Fausto Petrelli et al. Cancers
- Systematic review: Soluble immunological biomarkers in advanced non-small-cell lung cancer (NSCLC)
- (2020) Finn Mildner et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- The PD-1/PD-L pathway in rheumatic diseases
- (2020) Shuo Zhang et al. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
- Serum levels of soluble programmed death protein (sPD-1) and soluble programmed death ligand 1(sPD-L1) in systemic lupus erythematosus: association with activity and severity
- (2020) Yan Du et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities
- (2020) Yves Allenbach et al. AUTOIMMUNITY REVIEWS
- Risk of scleroderma according to the type of immune checkpoint inhibitors
- (2020) Benjamin Terrier et al. AUTOIMMUNITY REVIEWS
- Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy
- (2020) Lukas F. Mager et al. SCIENCE
- Low expressions of PD-L1 and CTLA-4 by induced CD4+CD25+ Foxp3+ Tregs in patients with SLE and their correlation with the disease activity
- (2020) Ling Zhao et al. CYTOKINE
- Decrease of T-cells exhaustion markers programmed cell death-1 and T-cell immunoglobulin and mucin domain-containing protein 3 and plasma IL-10 levels after successful treatment of chronic hepatitis C
- (2020) Sylwia Osuch et al. Scientific Reports
- PD-L1 Reverse Signaling in Dermal Dendritic Cells Promotes Dendritic Cell Migration Required for Skin Immunity
- (2020) Erin D. Lucas et al. Cell Reports
- Role of the PD-1/PD-L1 Dyad in the Maintenance of Pancreatic Immune Tolerance for Prevention of Type 1 Diabetes
- (2020) Marika Falcone et al. Frontiers in Endocrinology
- Depletion of LAG‐3 + T Cells Translated to Pharmacology and Improvement in Psoriasis Disease Activity: A Phase I Randomized Study of mAb GSK2831781
- (2020) Joanne Ellis et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- The innate immune system and cell death in autoinflammatory and autoimmune disease
- (2020) David E Place et al. CURRENT OPINION IN IMMUNOLOGY
- Strategies for improving the management of immune-related adverse events
- (2020) Aung Naing et al. Journal for ImmunoTherapy of Cancer
- The Role of the Thymus in the Immune Response
- (2019) Puspa Thapa et al. Thoracic Surgery Clinics
- Drug-induced systemic lupus erythematosus: should immune checkpoint inhibitors be added to the evolving list?
- (2019) Emanuel Raschi et al. ANNALS OF THE RHEUMATIC DISEASES
- Analysis of the PD-1/PD-L1 axis in human autoimmune thyroid disease: Insights into pathogenesis and clues to immunotherapy associated thyroid autoimmunity
- (2019) Daniel Álvarez-Sierra et al. JOURNAL OF AUTOIMMUNITY
- Role of CTLA4 A49G polymorphism in systemic lupus erythematosus and its geographical distribution
- (2019) Vikas Kailashiya et al. JOURNAL OF CLINICAL PATHOLOGY
- PD-1+CXCR5−CD4+T cells are correlated with the severity of systemic lupus erythematosus
- (2019) Jin Lin et al. RHEUMATOLOGY
- Abatacept in Early Diffuse Cutaneous Systemic Sclerosis – Results of a Phase 2 Investigator‐Initiated, Multicenter, Double‐Blind Randomized Placebo‐Controlled Trial
- (2019) Dinesh Khanna et al. Arthritis & Rheumatology
- Mechanisms Controlling PD-L1 Expression in Cancer
- (2019) Jong-Ho Cha et al. MOLECULAR CELL
- Abatacept in rheumatoid arthritis and the risk of cancer: a world observational post-marketing study
- (2019) Sibylle de Germay et al. RHEUMATOLOGY
- Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease
- (2018) Noha Abdel-Wahab et al. ANNALS OF INTERNAL MEDICINE
- Associations of Circulating CXCR3-PD-1+CD4+T cells with Disease Activity of Systemic Lupus Erythematosus
- (2018) Han Lei et al. Modern Rheumatology
- Increased Expression and Modulated Regulatory Activity of Coinhibitory Receptors PD-1, TIGIT, and TIM-3 in Lymphocytes From Patients With Systemic Sclerosis
- (2018) Michelle Fleury et al. Arthritis & Rheumatology
- Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens
- (2018) Romualdo Barroso-Sousa et al. JAMA Oncology
- LAG3+ Regulatory T Cells Restrain Interleukin-23-Producing CX3CR1+ Gut-Resident Macrophages during Group 3 Innate Lymphoid Cell-Driven Colitis
- (2018) David Bauché et al. IMMUNITY
- Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3
- (2018) Jun Wang et al. CELL
- Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors
- (2018) Omar Hasan Ali et al. EUROPEAN JOURNAL OF CANCER
- PD-1 immunobiology in systemic lupus erythematosus
- (2018) Colleen S. Curran et al. JOURNAL OF AUTOIMMUNITY
- Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: A retrospective analysis
- (2018) Teppei Yamaguchi et al. LUNG CANCER
- LAG-3 inhibits the activation of CD4+ T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII
- (2018) Takumi Maruhashi et al. NATURE IMMUNOLOGY
- LAG3 (CD223) as a cancer immunotherapy target
- (2017) Lawrence P. Andrews et al. IMMUNOLOGICAL REVIEWS
- Scleroderma Induced by Pembrolizumab: A Case Series
- (2017) Naiara S. Barbosa et al. MAYO CLINIC PROCEEDINGS
- Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis
- (2017) Deepak A. Rao et al. NATURE
- PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity
- (2017) Maria Gato-Cañas et al. Cell Reports
- Contribution of Soluble Forms of Programmed Death 1 and Programmed Death Ligand 2 to Disease Severity and Progression in Systemic Sclerosis
- (2017) Takemichi Fukasawa et al. Arthritis & Rheumatology
- Corrigendum: Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
- (2017) Vivek Kumar Frontiers in Pharmacology
- Extracellular Vesicles Transfer the Receptor Programmed Death-1 in Rheumatoid Arthritis
- (2017) Stinne R. Greisen et al. Frontiers in Immunology
- Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract
- (2017) Michael Dougan Frontiers in Immunology
- Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept
- (2016) Rieke Alten et al. BMC MUSCULOSKELETAL DISORDERS
- Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
- (2016) Ana C. Anderson et al. IMMUNITY
- Patient-Reported Outcomes From a Two-Year Head-to-Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid Arthritis
- (2016) Roy Fleischmann et al. ARTHRITIS CARE & RESEARCH
- Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management
- (2016) Paola Savoia et al. Human Vaccines & Immunotherapeutics
- Clinical efficacy of a new CD28-targeting antagonist of T cell co-stimulation in a non-human primate model of collagen-induced arthritis
- (2015) M. P. M. Vierboom et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells
- (2015) T. Kouo et al. Cancer Immunology Research
- LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses
- (2014) F. Xu et al. CANCER RESEARCH
- Early-onset Crohn’s disease and autoimmunity associated with a variant in CTLA-4
- (2014) Sebastian Zeissig et al. GUT
- Co-Inhibitory Pathways and Their Importance in Immune Regulation
- (2014) Naoka Murakami et al. TRANSPLANTATION
- Upregulated PD-1 Expression Is Associated with the Development of Systemic Lupus Erythematosus, but Not the PD-1.1 Allele of the PDCD1 Gene
- (2014) Qingqing Jiao et al. International Journal of Genomics
- Diverse Mechanisms Regulate the Surface Expression of Immunotherapeutic Target CTLA-4
- (2014) Helga Schneider et al. Frontiers in Immunology
- T-cell aging in rheumatoid arthritis
- (2013) Cornelia M. Weyand et al. CURRENT OPINION IN RHEUMATOLOGY
- Autoantibodies Present Before Symptom Onset in Primary Sjögren Syndrome
- (2013) Roland Jonsson JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Increased PD-1 on CD4+CD28− T cell and soluble PD-1 ligand-1 in patients with T2DM: Association with atherosclerotic macrovascular diseases
- (2013) Bimin Shi et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Increased soluble programmed death-1 (sPD-1) is associated with disease activity and radiographic progression in early rheumatoid arthritis
- (2013) SR Greisen et al. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
- Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis
- (2013) Meliha Crnkic Kapetanovic et al. ARTHRITIS RESEARCH & THERAPY
- Efficacy and Safety of Abatacept in Lupus Nephritis: A Twelve-Month, Randomized, Double-Blind Study
- (2013) Richard Furie et al. Arthritis & Rheumatology
- Role of the PD-1 Pathway in the Immune Response
- (2012) L. V. Riella et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Abatacept for Crohn's Disease and Ulcerative Colitis
- (2012) William J. Sandborn et al. GASTROENTEROLOGY
- The Inhibitory Receptor PD-1 Regulates IgA Selection and Bacterial Composition in the Gut
- (2012) S. Kawamoto et al. SCIENCE
- Antibody-mediated depletion of lymphocyte-activation gene-3 (LAG-3+)-activated T lymphocytes prevents delayed-type hypersensitivity in non-human primates
- (2011) N. Poirier et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Association of cytotoxic T lymphocyte associated antigen-4 gene (rs60872763) polymorphism with Crohn's disease and high levels of serum sCTLA-4 in Crohn's disease
- (2011) Zhitao Chen et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Cutting Edge: Accelerated Autoimmune Diabetes in the Absence of LAG-3
- (2011) M. Bettini et al. JOURNAL OF IMMUNOLOGY
- Autoantibodies predate the onset of systemic lupus erythematosus in northern Sweden
- (2011) Catharina Eriksson et al. ARTHRITIS RESEARCH & THERAPY
- The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: Results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial
- (2010) J. T. Merrill et al. ARTHRITIS AND RHEUMATISM
- Mechanisms of costimulation
- (2009) Arlene H. Sharpe IMMUNOLOGICAL REVIEWS
- CTLA4-Ig interacts with cultured synovial macrophages from rheumatoid arthritis patients and downregulates cytokine production
- (2009) Maurizio Cutolo et al. ARTHRITIS RESEARCH & THERAPY
- Association of an A/C single nucleotide polymorphism in programmed cell death-ligand 1 gene with Graves' disease in Japanese patients.
- (2008) Mina Hayashi et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started